BEPREVE Litigations
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6780877 | BAUSCH AND LOMB INC | Acid addition salt of optically active piperidine compound and process for preparing the same |
Sep, 2019
(4 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8877168 | BAUSCH AND LOMB INC | Aqueous liquid preparations and light-stabilized aqueous liquid preparations |
Jul, 2023
(8 months ago) | |
| US8784789 | BAUSCH AND LOMB INC | Aqueous liquid preparations and light-stabilized aqueous liquid preparations |
Jan, 2025
(8 months from now) | |
Bepreve is owned by Bausch And Lomb Inc.
Bepreve contains Bepotastine Besilate.
Bepreve has a total of 3 drug patents out of which 2 drug patents have expired.
Expired drug patents of Bepreve are:
- US8877168
- US6780877
Bepreve was authorised for market use on 08 September, 2009.
Bepreve is available in solution/drops;ophthalmic dosage forms.
Drug patent challenges can be filed against Bepreve from 08 September, 2013.
The generics of Bepreve are possible to be released after 13 January, 2025.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 08, 2014 |
Drugs and Companies using BEPOTASTINE BESILATE ingredient
NCE-1 date: 08 September, 2013
Market Authorisation Date: 08 September, 2009
Treatment: NA
Dosage: SOLUTION/DROPS;OPHTHALMIC
How can I launch a generic of BEPREVE before it's drug patent expiration?
More Information on Dosage
BEPREVE family patents
